International Journal of Clinical and Experimental Neurology
ISSN (Print): 2379-7789 ISSN (Online): 2379-7797 Website: http://www.sciepub.com/journal/ijcen Editor-in-chief: Zhiyou Cai, MD
Open Access
Journal Browser
Go
International Journal of Clinical and Experimental Neurology. 2017, 5(1), 11-17
DOI: 10.12691/ijcen-5-1-4
Open AccessArticle

Association of Cerebrospinal Fluid Tau Protein in Patients with Alzheimer’s and Non Alzheimer’s Dementias in a Tertiary Level Hospital in Bangladesh

Imran Sarker1, , Rezaul Karim Khan2, Anis Haque3, M A Hannan2, , Rafiqul Islam2, Abu Nasir Rizvi2, Ahsan Habib Helal2 and Subrata Kumar Biswas4

1Department of Neurology, National Institute of Neurosciences and Hospital, Sher-E-Banglanagar, Dhaka, Bangladesh

2Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh

3Consultant Neurologist, Conquest Hospital, The Ridge St.Leonard on Sea, East Sussex, TN377RD, UK.

4Department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh

Pub. Date: July 15, 2017

Cite this paper:
Imran Sarker, Rezaul Karim Khan, Anis Haque, M A Hannan, Rafiqul Islam, Abu Nasir Rizvi, Ahsan Habib Helal and Subrata Kumar Biswas. Association of Cerebrospinal Fluid Tau Protein in Patients with Alzheimer’s and Non Alzheimer’s Dementias in a Tertiary Level Hospital in Bangladesh. International Journal of Clinical and Experimental Neurology. 2017; 5(1):11-17. doi: 10.12691/ijcen-5-1-4

Abstract

Background: Alzheimer’s disease is one of the common causes of dementia in our country. The growth of the elderly population, together with the rising incidence of dementia requires immediate attention. There is very limited data regarding how CSF Tau protein correlates with this group of people’s cognitive function. Objectives: To evaluate association of CSF Tau protein in different types of dementia patients (AD and non-AD) and to find out the correlation of CSF Tau with severity of dementia and duration of disease. Methods: This cross sectional analytical study was conducted in dementia clinic (OPD) and inpatient department of Neurology, BSMMU from March’2013 to September’2015. 48 both male and female adult subjects were included in this study. Then they were divided into 3 groups: Alzheimer’s disease (AD) group (n=15), non-AD other dementias (OD) group (n=18) and subjects having neither AD and/or OD were included as control (n=15). CSF Tau protein was measured and compared between 3 groups. Results: Mean age of dementia in AD group was 68.2±9.33 years and in OD group was 67.72±12.74 years. Mean MMSE score in AD group was 13.47± 4.72, in OD group 15.83±3.31 and in control group 28.60±1.12. This study showed that CSF Tau protein was highly elevated in AD group (315.30±279.68 pg/ml) than in OD (57.08±27.41pg/ml) and control (39.23±12.21) groups. Conclusion: The study found that CSF Tau levels are elevated in AD patients in comparison to non AD other dementias. So, CSF Tau protein can be an early biomarker of Alzheimer’s disease.

Keywords:
Alzheimer’s disease ANOVA CSF Tau protein Dementia

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Dekosky ST, Kaufer DI, Hamilton RL, Wolk DA, Lopez OL. The Dementia. In Bradley WG, Daroff RB,Fenichel GM, Jankovic J, Editors, Neurology in clinical practice. 6th ed. Elsevier. Philadelphia 2008; 1856.
 
[2]  Ferri CP, Prince M, Brayne C. Alzheimer’s Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-17.
 
[3]  Rimmer E. WHO should work to develop Alzheimer’s standards. The Lancet 2005; 361: 3.
 
[4]  Whitehouse PJ, Sciulli CG, Mason RM. Dementia drug development: Use of information systems to harmonize global drug development. Psychopharmacol Bull 1997; 33:129-33.
 
[5]  McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human 57 Services Task Force on Alzheimer’s Disease. Neurology 1984; 34 (7): 939-44.
 
[6]  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV, Washington D.C 1994.
 
[7]  Lewczuk P, Esselmann H, Bibl M et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol. Neurosci 2004; 23: 115-22.
 
[8]  Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Sharma DR, Grover VK. Cerebrospinal fluid profile of amyloid b42 (Ab42), hTau and ubiquitin in North Indian Alzheimer’s disease patients. Neurosci. Lett 2011; 487: 134-38.
 
[9]  Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Neurology 2010; 6: 131-144.
 
[10]  Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-34.
 
[11]  Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol 2009; 66: 382-89.
 
[12]  Haense C, Buerger K, Kalbe E et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease. Eur. J. Neurol 2008; 15: 1155-62.
 
[13]  Hampel H, Goernitz A & Buerger K. Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull 2003; 61: 243-53.
 
[14]  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. Journal of Neurology, Neurosurgery, and Psychiatry 1994; 57(4): 416-418.
 
[15]  Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia 1994; 5:189-92.
 
[16]  Mohammad QD, Habib M, Bhowmik NB et al. Technical committee for the development of MMSE in Bangladesh. Dhaka. 2010.
 
[17]  Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull. 2003; 61: 243-253.
 
[18]  Islam MN, Moniruzzaman M, Khalil IM, Basri R, Alam MK, Loo WK. Burden of Stroke in Bangladesh. International journal of stroke 2012; 21: 1-3.
 
[19]  Albanese E, Banerjee S, Dhanasiri S et al. Dementia UK: A report by the Personal Social Services Research Unit (PSSRU), Institute of Psychiatry at King’s College London, for the Alzheimer’s Society 2007.
 
[20]  Bangladesh Bureau Of Statistics (BBS) 2015, Report On Sample Vital Registration System 2013, Bangladesh Bureau Of Statistics, Statistics And Informatics Division (SID), Ministry Of Planning, Government Of The People‘s Republic Of Bangladesh, Dhaka, Bangladesh.
 
[21]  World life expectancy 2015: http://www.geoba.se/population.php?pc=world&type=15.
 
[22]  Hofman A, Rocca WA, Brayne C et al.The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991; 20(3): 736-48.
 
[23]  Schmidt R, Kienbacher E, Benke T et al. Sex differences in Alzheimer's disease. Neuropsychiatr 2008; 22(1): 1-15.
 
[24]  Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference?. Neurobiol Aging 2001; 22(4): 575-80.
 
[25]  Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A. Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-30.
 
[26]  Hanisch K, Soininen H, Alafuzoff I, Hoffmann R. Analysis of human tau in cerebrospinal fluid. J Proteome Res 2010; 9:1476-82.
 
[27]  Sunderland T, Linker G, Mirza N et al. Decreased β-Amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease. Journal of American Medical Association 2003; 289: 2094.
 
[28]  Vickers JC, Riederer BM, Marugg DA. Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease. Neuroscience 1994; 62: 328-33.
 
[29]  Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26(3): 231-45.
 
[30]  Tato RE, Frank A, Hernanz A.Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995; 59: 280-83.